Research Articles >
College of Health Sciences >
Please use this identifier to cite or link to this item:
|Title: ||Effectiveness of Routine BCG Vaccination on Buruli Ulcer Disease: A Case-Control Study in the Democratic Republic of Congo, Ghana and Togo|
|Authors: ||Phillips, Richard Odame|
Phanzu, Delphin Mavinga
Luzolo, Elyse´e Kalundieko
Sarfo, Fred Stephen
Halatoko, Wemboo Afiwa...et.al.
|Issue Date: ||2015|
|Publisher: ||Plos Neglected Tropical Diseases|
|Citation: ||Phillips RO, Phanzu DM, Beissner M, Badziklou K, Luzolo EK, et al. (2015) Effectiveness of Routine BCG Vaccination on Buruli Ulcer Disease: A Case- Control Study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis 9(1): e3457. doi:10.1371/journal.pntd.0003457|
|Abstract: ||Background: The only available vaccine that could be potentially beneficial against mycobacterial diseases contains live
attenuated bovine tuberculosis bacillus (Mycobacterium bovis) also called Bacillus Calmette-Gue´rin (BCG). Even though the BCG
vaccine is still widely used, results on its effectiveness in preventing mycobacterial diseases are partially contradictory, especially
regarding Buruli Ulcer Disease (BUD). The aim of this case-control study is to evaluate the possible protective effect of BCG
vaccination on BUD.
Methodology: The present study was performed in three different countries and sites where BUD is endemic: in the
Democratic Republic of the Congo, Ghana, and Togo from 2010 through 2013. The large study population was comprised of
401 cases with laboratory confirmed BUD and 826 controls, mostly family members or neighbors.
Principal Findings: After stratification by the three countries, two sexes and four age groups, no significant correlation was
found between the presence of BCG scar and BUD status of individuals. Multivariate analysis has shown that the
independent variables country (p = 0.31), sex (p = 0.24), age (p = 0.96), and presence of a BCG scar (p = 0.07) did not
significantly influence the development of BUD category I or category II/III. Furthermore, the status of BCG vaccination was
also not significantly related to duration of BUD or time to healing of lesions.
Conclusions: In our study, we did not observe significant evidence of a protective effect of routine BCG vaccination on the risk of
developing either BUD or severe forms of BUD. Since accurate data on BCG strains used in these three countries were not
available, no final conclusion can be drawn on the effectiveness of BCG strain in protecting against BUD. As has been suggested
for tuberculosis and leprosy, well-designed prospective studies on different existing BCG vaccine strains are needed also for BUD.|
|Description: ||An article published by Phillips RO, Phanzu DM, Beissner M, Badziklou K, Luzolo EK, et al. (2015) Effectiveness of Routine BCG Vaccination on Buruli Ulcer Disease: A Case-
Control Study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis 9(1): e3457. doi:10.1371/journal.pntd.0003457|
|Appears in Collections:||College of Health Sciences|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.